yahoofinance logo_edited.jpg

Global Smart Sleep Tracking Products Market to Garner a Revenue of USD 11,234.55 Million by 2028 and Grow with a CAGR of 17.50% during 2020-2028; Surge in Concern for Sleep-Related Disorders to Drive the Market Growth.
Read more on Yahoo finance...


yahoofinance logo_edited.jpg

Gan Yavne, Israel; AppYea (OTC: APYP)
AppYea expands its SleepX patent commercialization portfolio with a non-diluting agreement.

SleepX signed a new commercialization agreement for two new patents. The SleepX PRO solution is designed to diagnose sleep apnea using only a smartphone, with no physical contact.
Read more on Yahoo finance...


Gan Yavne, Israel; AppYea (OTC: APYP)
Todd Violet has resigned as the company's director and CEO and shall be replaced by Bary Molchadsky, the company's chairman.


Gan Yavne, Israel; AppYea (OTC: APYP)
AppYea files consolidated 2020 and 2021audited financial statements. 
AppYea, which through its wholly owned subsidiary SleepX, is focused on the development of accurate wearable monitoring solutions to monitor and treat sleep apnea and snoring, is pleased to announce the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC).
Read more on OTC Markets...


Boca Raton, Florida; AppYea (OTC: APYP)
Symbol was changed back to APYP


Boca Raton, Florida; AppYea (OTC: APYPD)
Appyea to expand its patent portfolio, on a non-dilutive transaction.
SleepX (AppYea's subsidiary) is in advanced negotiations to sign an exclusive license agreement to commercialize 2 additional US patents in the field of monitoring and diagnosis of sleep apnea through speech analysis.


Boca Raton, Florida; AppYea (OTC: APYPD)
The Company reducing its authorized shares by 91% from 10 billion to 900 million.


Boca Raton, Florida; AppYea (OTC: APYPD)
We have completed the development of our application for treatment of snoring.


Boca Raton, Florida; AppYea (OTC: APYPD)
Company presentation


Boca Raton, Florida; AppYea (OTC: APYPD)
Annual report for the period ended 12/31/2021.


yahoofinance logo_edited.jpg

Boca Raton, Florida; AppYea (OTC: APYPD)
SleepX applies to the Helsinki Committee for approval on its clinical trial with the SleepX PRO smartphone application.
SleepX PRO is designed to diagnose sleep apnea using only a smartphone, and with no physical contact. 
Continue reading on yahoo finance...


Dear investors, due to the RS made, the symbol of the stock was changed to APYPD for three weeks. After that, it will return to be APYP again.
Keep track of our announcements as we continue to move forward.


Boca Raton, Florida; AppYea (OTC:APYPD)
SleepX completes the Beta stage of its wearable data-driven wristband ‘DreamIT’ to treat snoring.
Continue reading...


Boca Raton, Florida; AppYea (OTC:APYP)

We are proud to announce that Neil Kline, founder and former CEO of the American Sleep Association (ASA), joined the board of directors of AppYea.


yahoofinance logo_edited.jpg

Boca Raton, Florida; AppYea (OTC: APYP)

Biomedical AI entrepreneur Prof. Amir Geva appointed CSO of SleepX.

World renowned machine learning and bio-feedback expert joins company to execute and lead the development of DreamIT – the company’s patented solution integrating its proprietary AI technology in a wearable data driven wristband to treat sleep apnea and snoring.

Continue reading...


yahoofinance logo_edited.jpg

Boca Raton, Florida; AppYea (OTC: APYP)

AppYea completes acquisition of SleepX, entering a $6-9 billion sleep treatments market: expects to begin marketing during 2H2022

Continue reading...


yahoofinance logo_edited.jpg

AppYea takes steps for Future Growth

Continue reading...



yahoofinance logo_edited.jpg

Israeli SleepX to be merged into AppYea Inc. (APYP)

A revolutionary AI approach to the problem of snoring

Continue reading...


Nevada, Sept 8, 2021. AppYea continues the process of merging SleepX into the company. The merger is expected to be completed by 12/01/2021 in accordance with the model published on 08/02/2021.

Continue reading...



Following the update on 02/23/2021, a final payment was made to the University as part of a patent rights license agreement.



Filed on August 10, 2021: Reply to exam report IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 

Appl. No. 14/404,621
Filed: 11/30/2014


APYP Merger News:

AppYea, Inc. and SleepX Ltd. Agree to Securities Exchange Agreement.

New York, NY, August 02, 2021 (GLOBE NEWSWIRE) -- AppYea, Inc. (OTCPINK: APYP) announced today that it has entered into a Securities Exchange Agreement with SleepX Ltd., an Israeli company ("SleepX") and the shareholders of SleepX pursuant to which SleepX would become a wholly-owned subsidiary of APYP, and the shareholders of SleepX would receive such number of shares of common stock of APYP as described below. Continue reading...


InsiderFinancial - logo_edited.jpg


AppYea, Inc has been correcting during the last five days, but the OTC stock is on track to become a major winner in the coming months. The share price fell 44% to $0.0041 and is likely to find strong support at $0.0037. The price hit $0.0077 on July 9, getting close to February’s one cent, which remains the highest level year-to-date (YTD) and since 2015. Still, the long-term bull run is only making its first steps.

Continue reading...



seeking alpha logo_edited.jpg

Seeking Alpha - New Sleep Apnea Wrist Band Could Replace Uncomfortable CPAP Masks In $3.7B Sleeping Disorder Market

The global sleep apnea devices market size was valued at USD 3.7 billion in 2020 and is expected to expand at a compound annual growth rate of 6.2% from 2021 to 2028. Sleep apnea is a sleeping disorder, characterized by irregular breathing, thus providing insufficient oxygen to the brain. According to an American Sleep Association study published in 2020, an estimated 50 million to 70 million people in the U.S. are suffering from some form of sleep disorders. Moreover, according to Canadian Respiratory Journal in 2014, around 5.4 million adults in Canada were diagnosed with sleep apnea or were at higher risk of developing OSA. According to a study conducted by ResMed in 2018, around 175 million people in Europe were suffering from sleep apnea. Continue reading...


Paid 60% of the payment for the University's Patent License Agreement.

Examines an engagement with a leading law firm specializing in patent litigation and intellectual property protection. Vew our IP portfolio



Advancing to next stage! Click to see the public disclosure


Following the public disclosure of the LOI amongst our companies and APPYA Inc. (OTCPINK: APYP),
we are pleased to announce that we have reached preliminary understandings on the principal terms of the acquisition and are working towards it.

We believe that the acquisition should provide significant value for all parties and allow the DreamIT X3, our principal anti-snoring product, to reach the market as early as the first half of 2022 under the “Wellness Gadgets” category, which will allow for a shorter time for the market.

We believe that there is a pressing need for the device. According to the American National Sleep Foundation in the United States, 57% of men and 40% of women suffer from chronic snoring https://www.sleepfoundation.org/snoring

DreamIT X3 is based on a unique technology that is patents protected and is a revolutionary solution to snoring. We believe the unit retael price should  not exced $149.


We are excited to begin working with our US strategic partners to realize our business vision!

Нью-Йоркское отделение